Jatenergy’s Green Forest inks strategic distro deal

|

Published 07-SEP-2018 10:26 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Green Forest — 50% owned subsidiary of Jatenergy (ASX:JAT) — has clinched a distribution deal to supply China National Pharmaceutical Group Corporation (Sinopharm) with its Australian product range.

Sinopharm is of the world’s biggest pharmaceutical companies, with over 5,000 stores across China. It ranks 194th in Fortune’s 2018 Global 500 and is the sixth largest pharma company on that list, with annual revenue of USD $51.8 billion in 2017.

Sinopharm is also the largest Chinese medical and healthcare group directly managed by the state-owned Assets Supervision and Administration Commission of the State Council (SASAC).

Green Forest, meanwhile, is a Sydney-based wholesaler, distributor and exporter, which sells to more than 50 shops and pharmacies in Hong Kong, and over 200 gift shops, duty free stores and daigou (‘personal shopper’) warehouses in Australia, as well as Chinese cross-border platforms like Taobao and WeChat.

Green Forest’s range includes vitamins, cosmetics, dairy products and a range of other health-related consumer goods.

Sinopharm is establishing a new online-to-offline (O2O) sales channel for its 5,000 plus retail stores across China, including the GuoDa Pharmacies, which are operated by Sinopharm Holding GuoDa Drugstore Co., Lt — a national chain operating more than 3,800 retail pharmacies in over 70 Chinese cities.

Green Forest will supply Australian consumer goods to Sinopharm for sale through the O2O sales channel. Chinese consumers will be able to receive Green Forest products by home delivery from a cross-border bonded warehouse or direct from Australia.

O2O shopping is increasingly popular in China. Consumers can familiarise themselves with products in their local retail store which aren’t available through domestic distribution channels — they can then scan the product’s QR code to make the purchase and order home delivery.

“O2O is a large and growing part of China’s retail landscape and we are delighted to be part of Sinopharm’s national O2O rollout,” JAT executive director, Wilton Yao, said. “This is a great opportunity for JAT and for the brands we represent.”

However, it is an early stage of this company’s development and if considering this stock for your portfolio you should take all public information into account and seek professional financial advice.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X